阿达木单抗高剂量与标准诱导方案及两种维持策略比较:随机SERENE CD试验结果
SERENE CD试验是一项3期随机双盲多中心研究,纳入中重度活动性克罗恩病成人患者,比较阿达木单抗高剂量诱导方案(第0、1、2、3周160 mg)与标准诱导方案(第0周160 mg、第2周80 mg),以及临床调整(CA)与治疗药物监测(TDM)两种维持策略。结果显示高剂量诱导在临床缓解和内镜应答上均未优于标准诱导,CA与TDM维持疗效相似,安全性相当。
要点
- 高剂量与标准诱导方案第4周临床缓解率均为44%,无显著差异(P = .939)
- 第12周内镜应答率高剂量组43% vs 标准组39%,无显著差异(P = .462)
- CA与TDM维持策略第56周疗效相似,安全性相当
核心结论
- 高剂量诱导方案未优于标准诱导方案,CA与TDM维持策略疗效相似,阿达木单抗耐受性良好,未发现新的安全性问题。
研究设计与样本
- 3期随机双盲多中心试验,纳入中重度活动性克罗恩病成人患者(CDAI评分220-450、内镜下黏膜炎症证据、既往标准治疗失败)。
- 高剂量诱导组:阿达木单抗第0、1、2、3周各160 mg,n=308;标准诱导组:第0周160 mg、第2周80 mg,n=206;第4周起均40 mg隔周一次。
- 第12周重新随机分为CA维持组(n=92)和TDM维持组(n=92),探索性终点评估至第56周。
主要发现
- 第4周临床缓解率:高剂量组44% vs 标准组44%(P = .939)。
- 第12周内镜应答率:高剂量组43% vs 标准组39%(P = .462)。
- 第56周CA与TDM维持策略疗效相似。
- 两种给药方案安全性特征相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Dose-optimization strategies for biologic therapies in Crohn's disease (CD) are not well established. The SERENE CD (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Crohn's Disease) trial evaluated higher vs standard adalimumab induction dosing and clinically adjusted (CA) vs therapeutic drug monitoring (TDM) maintenance strategies in patients with moderately to severely active CD. METHODS: In this phase 3, randomized, double-blind, multicenter trial, eligible adults (Crohn's Disease Activity Index score of 220-450, endoscopic evidence of mucosal inflammation, and previous failure of standard therapies) were randomized to higher induction regimen (adalimumab 160 mg at weeks 0, 1, 2, and 3; n = 308) or standard induction regimen (adalimumab 160 mg at week 0 and 80 mg at week 2; n = 206) followed by 40 mg every other week from week 4 onward. Co-primary end points included clinical remission at week 4 and endoscopic response at week 12. At week 12, patients were re-randomized to maintenance therapy optimized by Crohn's Disease Activity Index and C-reactive protein (CA; n = 92) or serum adalimumab concentrations and/or clinical criteria (TDM; n = 92); exploratory end points were evaluated at week 56. RESULTS: Similar proportions of patients receiving higher induction regimen and standard induction regimen achieved clinical remission at week 4 (44% in both; P = .939) and endoscopic response at week 12 (43% vs 39%, respectively, P = .462). Week 56 efficacy was similar between CA and TDM. Safety profiles were comparable between dosing regimens. CONCLUSIONS: Higher induction regimen was not superior to standard induction regimen, and CA and TDM maintenance strategies were similarly efficacious. Adalimumab therapy was well tolerated, and no new safety concerns were identified. (ClinicalTrials.gov, Number: NCT02065570).
引用
- D'Haens GR, Sandborn WJ, Loftus EV, et al. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022. PMID: 35122766. doi:10.1053/j.gastro.2022.01.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。